Capecitabine Drug Profile

Boxed warning

Anticoagulant response (warfarin) dramatically increased
DPD deficiency causes severe toxicity

Clinical alerts

Boxed warning

2 boxed warnings

Narrow therapeutic index

Small dose changes can cause toxicity or loss of effect

Hepatotoxic

Monitor liver function

Mechanism of action

Oral prodrug converted to 5-FU preferentially in tumor tissue; inhibits thymidylate synthase

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Colorectal Cancer
·Liver Metastasis
·LDRT
·Metastatic Colorectal Carcinoma
·Metastatic Malignant Solid Neoplasm

Interactions

No curated interaction pairs are recorded for Capecitabine. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Diarrhea
Hand-foot syndrome
Nausea
Stomatitis
Myelosuppression

Food, alcohol & herbal

Food

Take within 30 minutes after meals

Alcohol · minor

No significant interaction

Pharmacokinetics

Half-life: 0.75 hours (5-FU terminal: 0.5-1 hour)
Protein binding: <60%
Metabolised by: Carboxylesterase, Cytidine deaminase
Inhibits: CYP2C9

Pregnancy & lactation

Not recorded for Capecitabine. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.